Effects of AZD1775 on the PK substrates for CYP3A, CYP2C19, CYP1A2 and on QT interval in patients with advanced cancer

Trial Identifier: D6014C00006
Sponsor: AstraZeneca
Collaborator:
Quintiles, Inc.
NCTID:: NCT03333824
Start Date: December 2017
Primary Completion Date: January 2019
Study Completion Date: January 2019
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
US, AZ Tucson, AZ, US, 85724
US, CA Los Angeles, CA, US, 90048
US, IN Indianapolis, IN, US, 46202
US, MD Silver Spring, MD, US, 20910
US, NH Lebanon, NH, US, 03756
US, RI Providence, RI, US, 02903
US, SC Greenville, SC, US, 29605
US, TX Houston, TX, US, 77030